Literature DB >> 25019433

Abdominal and pelvic complications of nonoperative oncologic therapy.

Chitra Viswanathan1, Mylene T Truong, Tara L Sagebiel, Yulia Bronstein, Raghunandan Vikram, Madhavi Patnana, Paul M Silverman, Priya R Bhosale.   

Abstract

Oncologic patients are treated with a combination of chemotherapy, radiation therapy, and surgery. Advances in therapeutic options have greatly improved the survival of patients with cancer. Examples of these advances are newer chemotherapeutic agents that target the cell receptors and advanced radiation therapy delivery systems. It is imperative that radiologists be aware of the variety of imaging findings seen after therapy in patients with cancer. Complications may occur with classic cytotoxic therapies (eg, 5-fluorouracil), usually at higher or prolonged doses or when administered to radiosensitive areas. Newer targeted systemic agents, such as bevacizumab and imatinib, have associated characteristic toxicities because their effects on cells do not depend on dose. Radiation may induce early and late effects in local normal tissues that may be seen at imaging. Imaging findings after chemotherapy include fatty liver, pseudocirrhosis, hepatic veno-occlusive disease, and splenic rupture. Complications of radiation therapy include large and small bowel strictures and radiation-induced hepatitis and tumors. Awareness of the various therapeutic options and knowledge of the spectrum of posttherapeutic complications allows radiologists to provide a comprehensive report that may impact patient management. ©RSNA, 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25019433     DOI: 10.1148/rg.344140082

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  7 in total

1.  Radiation-induced liver injury mimicking liver metastases on FDG-PET-CT after chemoradiotherapy for esophageal cancer : A retrospective study and literature review.

Authors:  Francine E M Voncken; Berthe M P Aleman; Jolanda M van Dieren; Cecile Grootscholten; Ferry Lalezari; Johanna W van Sandick; Jeffrey D Steinberg; Erik Vegt
Journal:  Strahlenther Onkol       Date:  2017-10-19       Impact factor: 3.621

2.  Diagnostic value/performance of radiological liver imaging during chemoterapy for gastrointestinal malignancy: a critical review.

Authors:  Alfonso Reginelli; Giovanna Vacca; Nicoletta Zanaletti; Teresa Troiani; Raffaele Natella; Nicola Maggialetti; Pierpaolo Palumbo; Andrea Giovagnoni; Fortunato Ciardiello; Salvatore Cappabianca
Journal:  Acta Biomed       Date:  2019-04-24

3.  Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.

Authors:  Reetta Holma; Reijo Laatikainen; Helena Orell; Heikki Joensuu; Katri Peuhkuri; Tuija Poussa; Riitta Korpela; Pia Österlund
Journal:  Nutrients       Date:  2020-02-04       Impact factor: 5.717

4.  Mesenteric panniculitis mimicking early recurrence at end-of-treatment evaluation in malignant lymphoma: Differentiation by active surveillance with F-18 FDG PET/CT imaging.

Authors:  Mitsutomi Ishiyama; Manuela Matesan
Journal:  Radiol Case Rep       Date:  2020-05-13

Review 5.  Chemotherapy-induced bowel ischemia: diagnostic imaging overview.

Authors:  Alfonso Reginelli; Angelo Sangiovanni; Giovanna Vacca; Maria Paola Belfiore; Maria Pignatiello; Giuseppe Viscardi; Alfredo Clemente; Fabrizio Urraro; Salvatore Cappabianca
Journal:  Abdom Radiol (NY)       Date:  2021-04-03

6.  Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective.

Authors:  Danny Ngo; Jemianne Bautista Jia; Christopher S Green; Anjalie T Gulati; Chandana Lall
Journal:  Insights Imaging       Date:  2015-10-06

7.  Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.

Authors:  Linda Calistri; Vieri Rastrelli; Cosimo Nardi; Davide Maraghelli; Sofia Vidali; Michele Pietragalla; Stefano Colagrande
Journal:  World J Gastroenterol       Date:  2021-12-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.